QRxPharma Limited (QRXPY)

[ErnieBilco]

ASX RELEASE
31 July 2014
GENERAL SHAREHOLDER UPDATE
Sydney, Australia and Bedminster, New Jersey – QRxPharma Limited (ASX: QRX and OTCQX:
QRXPY) today provided a brief general shareholder update following the Board changes announced
on 9 July.
Business Review
In recent weeks the new Board has been assisted and supported by the management team in closely
examining all key aspects of the business. A detailed review is currently underway, with particular
emphasis being given to the clinical development, regulatory, commercial and financial position of the
Company.
The Company expects within the next two weeks to receive the final minutes of the End of Review
(EOR) meeting regarding the Moxduo® New Drug Application (NDA), which was held with the
United States Food and Drug Administration (FDA) on 9 July. The Board and senior management
plan to meet soon thereafter to consider a range of strategic alternatives for the business. The
Company is in the process of finalising the Financial Report for the year ended 30 June 2014 and the
Board anticipates providing shareholders with a more detailed strategic and financial update by the
end of August.
Board Composition
The Board of Directors is giving careful consideration to the composition of the Board and the
optimum mix of skills and experience of Directors required for the Company at this stage. Further
appointments to the Board are anticipated in the near term.
###
For more information please contact:
Edward M Rudnic, Ph.D.
Chief Executive Officer
Tel: [phone]
Email: [e-mail]
Chris J Campbell
Chief Financial Officer and Company Secretary
Tel: [phone]
Email: [e-mail]